Because the aggregation of tau into small soluble species occurs in early stages of tauopathies such as Alzheimer’s disease, we have investigated how these aggregates modify hippocampal function, which may contribute to cognitive deficits. This evidence concerns the gene MAPT and Cognitive impairment.